Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
JPY 49.0
(0.0%)
JPY 49.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.01 Billion JPY | -31.76% |
| 2022 | 4.41 Billion JPY | -8.54% |
| 2021 | 4.83 Billion JPY | -27.79% |
| 2020 | 6.69 Billion JPY | -23.44% |
| 2019 | 8.74 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.69 Billion JPY | -10.73% |
| 2024 Q2 | 2.34 Billion JPY | -13.01% |
| 2023 FY | 3.01 Billion JPY | -31.74% |
| 2023 Q2 | 3.77 Billion JPY | -6.2% |
| 2023 Q1 | 4.02 Billion JPY | -8.92% |
| 2023 Q3 | 3.51 Billion JPY | -7.03% |
| 2023 Q4 | 3.01 Billion JPY | -14.06% |
| 2022 Q3 | 4.7 Billion JPY | 0.0% |
| 2022 Q4 | 4.41 Billion JPY | -6.07% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 54.229% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -148.963% |
| GNI Group Ltd. | 62.39 Billion JPY | 95.166% |
| Linical Co., Ltd. | 18.53 Billion JPY | 83.732% |
| Trans Genic Inc. | 9.81 Billion JPY | 69.259% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 46.469% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 56.58% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 48.146% |
| AnGes, Inc. | 28.89 Billion JPY | 89.561% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -247.756% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.081% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -86.336% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 40.528% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 30.665% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -23.97% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -27.077% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 56.481% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -72.2% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 40.695% |
| PeptiDream Inc. | 67.12 Billion JPY | 95.507% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -47.8% |
| Ribomic Inc. | 3.54 Billion JPY | 14.977% |
| SanBio Company Limited | 5.04 Billion JPY | 40.245% |
| Healios K.K. | 15.15 Billion JPY | 80.099% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -145.152% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -104.592% |
| StemRIM | 9.08 Billion JPY | 66.784% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 56.161% |
| FunPep Company Limited | 2.49 Billion JPY | -21.069% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -15.174% |
| Stella Pharma Corporation | 3.82 Billion JPY | 21.06% |
| TMS Co., Ltd. | 3.55 Billion JPY | 15.156% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 47.811% |
| Cuorips Inc. | 6.18 Billion JPY | 51.235% |
| K Pharma,Inc. | 3.31 Billion JPY | 8.989% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.552% |
| ReproCELL Incorporated | 9.05 Billion JPY | 66.684% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -11.073% |
| StemCell Institute Inc. | 6.54 Billion JPY | 53.905% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 56.845% |
| CellSeed Inc. | 2.46 Billion JPY | -22.315% |